4.4 Review

Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments

Journal

CLINICAL LUNG CANCER
Volume 22, Issue 6, Pages 483-499

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2021.07.011

Keywords

NSCLC; Review; SCLC; ADC; Therapeutics

Categories

Ask authors/readers for more resources

ADCs combine the specificity of a monoclonal antibody with the cytotoxic effects of chemotherapy to facilitate targeted delivery of cytotoxic payloads to cancer cells. ADCs show promise in lung cancer treatment, with future applications looking increasingly relevant.
While both targeted therapy and immunotherapy-based strategies have emerged as frontline standard-of-care for patients with advanced lung cancer, acquired resistance and disease progression remain inevitable in most cases. Chemotherapy is a common salvage option in this scenario, but is limited by a relatively narrow therapeutic index. The emergence of antibody-drug conjugates (ADCs) offer an appealing alternative. ADCs couple the specificity of a monoclonal antibody with the cytotoxic effects of chemotherapy to facilitate the targeted delivery of cytotoxic payloads directly to cancer cells. Here, we review the general structure and function of ADCs, followed by a discussion of emerging ADCs in lung cancer and the future applications of this increasingly relevant class of novel agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available